Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza

Lachant, D.; Roto, Dominick; Rappaport, Stephen; Prasad, Paritosh; Lachant, Neil A.; White, Robert J.

doi:10.1016/j.thromres.2021.07.003

Cited by 4 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, it is not surprising that a platelet‐derived protein would be up‐regulated in COVID‐19, as opposed to influenza. 48 , 49 These findings, combined with our data, suggest that both RAGE and PPBP are potential biomarkers to predict severity of COVID‐19. As RAGE and PPBP levels have been measured before in bronchoalveolar fluid in previous studies, future research should focus upon measuring these markers in bronchoalveolar fluid from patients in the early stage of COVID‐19 to predict disease severity.…”

Section: Discussionsupporting

confidence: 58%

“…Several studies suggest that the incidence of thrombotic complications in hospitalised patients with COVID‐19 patients is higher than in patients hospitalised with influenza. Therefore, it is not surprising that a platelet‐derived protein would be up‐regulated in COVID‐19, as opposed to influenza 48,49 . These findings, combined with our data, suggest that both RAGE and PPBP are potential biomarkers to predict severity of COVID‐19.…”

Section: Discussionsupporting

confidence: 57%

See 1 more Smart Citation

Increase of mast cells in COVID‐19 pneumonia may contribute to pulmonary fibrosis and thrombosis

et al. 2022

View full text Add to dashboard Cite

Aims Lung tissue from COVID‐19 patients shares similar histomorphological features with chronic lung allograft disease, also suggesting activation of autoimmune‐related pathways in COVID‐19. To more clearly understand the underlying spectrum of pathophysiology in COVID‐19 pneumonia, we analysed mRNA expression of autoimmune‐related genes in post‐mortem lung tissue from COVID‐19 patients. Methods and results Formalin‐fixed, paraffin‐embedded lung tissue samples of 18 COVID‐19 patients and eight influenza patients were used for targeted gene expression profiling using NanoString technology. Multiplex immunofluorescence for tryptase and chymase was applied for validation. Genes related to mast cells were significantly increased in COVID‐19. This finding was strengthened by multiplex immunofluorescence also showing a significant increase of tryptase‐ and chymase‐positive cells in COVID‐19. Furthermore, receptors for advanced glycation end‐products (RAGE) and pro‐platelet basic protein (PPBP) were up‐regulated in COVID‐19 compared to influenza. Genes associated with Type I interferon signalling showed a significant correlation to detected SARS‐CoV2 pathway‐related genes. The comparison of lung tissue samples from both groups based on the presence of histomorphological features indicative of acute respiratory distress syndrome did not result in finding any specific gene or pathways. Conclusion Two separate means of measuring show a significant increase of mast cells in SARS‐CoV‐2‐infected lung tissue compared to influenza. Additionally, several genes involved in fibrosis and thrombosis, among which are RAGE and PPBP, are up‐regulated in COVID‐19. As mast cells are able to induce thrombosis and fibrosis, they may play an important role in the pathogenesis of COVID‐19.

show abstract

Section: Discussionsupporting

confidence: 58%

Section: Discussionsupporting

confidence: 57%

Increase of mast cells in COVID‐19 pneumonia may contribute to pulmonary fibrosis and thrombosis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The effect size was quantified using the pooled odds ratio (OR) along with a 95% confidence interval (CI). Some studies ( 18 , 20 , 21 , 24 , 25 , 27–29 ) reported the length of hospital or ICU stays as a median with a range. To consolidate data, we estimated the mean and variance using a validated formula based on the reported median, range, and sample size ( 33 ).…”

Section: Methodsmentioning

confidence: 99%

Acute kidney injury in patients with COVID-19 compared to those with influenza: a systematic review and meta-analysis

Hsiao,

Pan,

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundCOVID-19 and influenza can both lead to acute kidney injury (AKI) as a common complication. However, no meta-analysis has been conducted to directly compare the incidence of AKI between hospitalized patients with COVID-19 and influenza. The objective of our study aims to investigate the incidence and outcomes of AKI among hospitalized patients between these two groups.Materials and methodsA systematic search of PubMed, Embase, and Cochrane databases was conducted from December 2019 to August 2023 to identify studies examining AKI and clinical outcomes among hospitalized patients with COVID-19 and influenza. The primary outcome of interest was the incidence of AKI, while secondary outcomes included in-hospital mortality, recovery from AKI, hospital and ICU stay duration. The quality of evidence was evaluated using Cochrane and GRADE methods.ResultsTwelve retrospective cohort studies, involving 17,618 hospitalized patients with COVID-19 and influenza, were analyzed. COVID-19 patients showed higher AKI incidence (29.37% vs. 20.98%, OR: 1.67, 95% CI 1.56–1.80, p < 0.01, I2 = 92.42%), and in-hospital mortality (30.95% vs. 5.51%, OR: 8.16, 95% CI 6.17–10.80, p < 0.01, I2 = 84.92%) compared to influenza patients with AKI. Recovery from AKI was lower in COVID-19 patients (57.02% vs., 80.23%, OR: 0.33, 95% CI 0.27–0.40, p < 0.01, I2 = 85.17%). COVID-19 patients also had a longer hospital stay (SMD: 0.69, 95% CI 0.65–0.72, p < 0.01, I2 = 98.94%) and longer ICU stay (SMD: 0.61, 95% CI 0.50–0.73, p < 0.01, I2 = 94.80%) than influenza patients. In our study, evidence quality was high (NOS score 7–9), with low certainty for AKI incidence and moderate certainty for recovery form AKI by GRADE assessment.ConclusionCOVID-19 patients had higher risk of developing AKI, experiencing in-hospital mortality, and enduring prolonged hospital/ICU stays in comparison to influenza patients. Additionally, the likelihood of AKI recovery was lower among COVID-19 patients.

show abstract

“…[6][7][8][9][10][11][12] Recent studies reported that COVID-19 patients were 3 to 6 times more likely to develop any arterial or venous thrombosis compared to patients affected by other infectious respiratory illnesses. [13][14][15][16] Although extensive, most of the data indicating a higher thrombotic risk associated with COVID-19 has been gathered based on comparisons with cohorts of patients with other respiratory infections in the pre-COVID-19 era. [13][14][15][16][17][18][19] While studies of this kind have provided valuable initial insight into the hemostatic changes caused by COVID-19, an important limitation to the use of historical cohorts is the change in practice patterns over the years.…”

Section: Introductionmentioning

confidence: 99%

“…[13][14][15][16] Although extensive, most of the data indicating a higher thrombotic risk associated with COVID-19 has been gathered based on comparisons with cohorts of patients with other respiratory infections in the pre-COVID-19 era. [13][14][15][16][17][18][19] While studies of this kind have provided valuable initial insight into the hemostatic changes caused by COVID-19, an important limitation to the use of historical cohorts is the change in practice patterns over the years. As a result, differences in hospital protocol regarding disease management, thromboprophylaxis regimen, and diagnostic method for thrombosis to which COVID-19 and non-COVID-19 patients were subjected could impact the incidence of thrombotic events in these study groups, and thus influence how we interpret the thrombotic risk associated with the clinical conditions in question.…”

Section: Introductionmentioning

confidence: 99%

Thrombosis Occurrence in COVID-19 Compared With Other Infectious Causes of ARDS: A Contemporary Cohort

Coy-Canguçu

Locachevic

Mariolano

et al. 2023

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Thrombosis occurrence in coronavirus disease 2019 (COVID-19) has been mostly compared to historical cohorts of patients with other respiratory infections. We retrospectively evaluated the thrombotic events that occurred in a contemporary cohort of patients hospitalized between March and July 2020 for acute respiratory distress syndrome (ARDS) according to the Berlin Definition and compared those with positive and negative real-time polymerase chain reaction results for wild-type severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) using descriptive analysis. The association between COVID-19 and thrombotic risk was evaluated using logistic regression. 264 COVID-19-positive (56.8% male, 59.0 years [IQR 48.6-69.7], Padua score on admission 3.0 [2.0-3.0]) and 88 COVID-19-negative patients (58.0% male, 63.7 years [51.2-73.5], Padua score 3.0 [2.0-5.0]) were included. 10.2% of non-COVID-19 and 8.7% of COVID-19 patients presented ≥ 1 clinically relevant thrombotic event confirmed by imaging exam. After adjustment for sex, Padua score, intensive care unit stay, thromboprophylaxis, and hospitalization length, the odds ratio for thrombosis in COVID-19 was 0.69 (95% CI, 0.30-1.64). We, therefore, conclude that infection-induced ARDS carries an inherent thrombotic risk, which was comparable between patients with COVID-19 and other respiratory infections in our contemporary cohort.

show abstract

Venous thromboembolism associates with SARS-CoV-2 more than seasonal influenza

Cited by 4 publications

References 9 publications

Increase of mast cells in COVID‐19 pneumonia may contribute to pulmonary fibrosis and thrombosis

Increase of mast cells in COVID‐19 pneumonia may contribute to pulmonary fibrosis and thrombosis

Acute kidney injury in patients with COVID-19 compared to those with influenza: a systematic review and meta-analysis

Thrombosis Occurrence in COVID-19 Compared With Other Infectious Causes of ARDS: A Contemporary Cohort

Contact Info

Product

Resources

About